AZN AstraZeneca AB Forward P/S Multiple

Symbol and logo of brand AstraZeneca Corp. (AZN)

Patent risks and regulatory price controls are weighing on the stability of AstraZeneca PLC (AZN). The forward P/S valuation reflects the dynamics of these factors, smoothing out market noise. Efficiency is being enhanced through outsourced manufacturing and logistics, as well as the active acquisition of biotech startups to refresh the portfolio. The value of 2.90 serves as the final mark for this indicator's level.

AZN AstraZeneca Plc: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for AstraZeneca Corp. (AZN)

- current price and projected stock value:
Stock Price AstraZeneca|AZN - Analyst Target Range
- market capitalization data:
Market Capitalization AstraZeneca Corp.|AZN - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share AstraZeneca|AZN - Book Valuation of Business|Market Cap to Net Assets Ratio astrazeneca.com|AZN - Aggregate Business Assets
- issuer credit burden and liquidity indicators:
Debt to Equity AstraZeneca PLC|AZN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital AstraZeneca PLC|AZN - Company Aggregate Debts|Debt to Book Value AstraZeneca Corp.|AZN - Long-Term Liabilities|Company Short-Term Debts AstraZeneca|Quick Liquidity astrazeneca.com
- business earnings and investment ratios data:
AZN - Company Profit|Projected Future Earnings AstraZeneca PLC|AZN - Market Cap to Earnings|Forward P/E Multiple AstraZeneca AB|AZN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple AstraZeneca Corp.|AZN - Operating profit EBITDA|Net earnings per share for the last 12 months AstraZeneca|AZN - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months astrazeneca.com|AZN - Earnings per share trend in current year|Net earnings per share growth forecast for next year AstraZeneca PLC
- sales volume and revenue indicators:
AZN - Company Revenue|Projected Sales Volume AstraZeneca|AZN - Market Cap to Revenue|Forward P/S Multiple AstraZeneca Corp.
Fundamental company analysis:AstraZeneca (AZN)
Original product of AstraZeneca Corp.

Forward P/S measures an asset's market value relative to projected revenue, allowing for the determination of the premium paid for future business growth. The dynamics of this multiple help investors assess the stability of the control premium during periods of volatility. By analyzing the forward price-to-sales valuation, one can observe how geopolitical barriers and component logistics disruptions at AstraZeneca PLC (AZN) impact expectations for future sales.

Direct competitors

Forward P/S Multiple LLY (Eli Lilly)|Projected Price to Revenue AbbVie Inc|Novartis Inc. - Forward P/S Multiple|MRK - Forward P/S Multiple|Novo Nordisk A/S (NVO) - Price-to-Projected Revenue Ratio|AMGN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PFE|SNY (Sanofi SA) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio BMS (BMY)|GSK (gsk.com) - Forward Price to Sales|Forward P/S Multiple TAK (Takeda Pharmaceutical)|Forward P/S Multiple tevapharm.com TEVA|RDY: Forward Price-to-Revenue Multiple|Future Price to Revenue VTRS|ROIV: Forward P/S Multiple|Market Cap to Future Revenue Ratio Zai Lab Corp (ZLAB)|Price-to-Projected Revenue Ratio Bausch Health Companies|Market Cap to Projected Revenue COSM (cosmosholdingsinc.com)